Two-Year Sapien Data Affirms Durability, And The Importance Of Avoiding Leaks
This article was originally published in The Gray Sheet
Mortality rates remained statistically indistinguishable after two years among patients receiving either Edwards Lifesciences’ Sapien transcatheter aortic heart valve or open surgical valve replacement in the firm’s PARTNER trial. Transcatheter aortic valve leaks were highlighted as a primary target for improving survival.
You may also be interested in...
Edwards is betting on next-generation Sapien devices and efforts towards a transcatheter mitral valve, as Medtronic and other competitors move closer to threatening the firm’s TAVR leadership position.
Edwards Lifesciences’ first-to-market transcatheter valve is safe and effective, and its benefits outweigh its risks in an expanded patient population, an FDA advisory panel says.
Recent launch of the transcatheter aortic heart valve for patients too sick for open heart surgery may get a lift from data presented at TCT.